NLS Pharmaceutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system disorders with unmet medical needs. Co.'s main compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary controlled release formulation, is being developed for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). Co.'s focus includes its primary product candidate: Quilience, for the treatment of excessive daytime sleepiness and cataplexy associated with narcolepsy, and Nolazol, for the treatment of ADHD. The NLSP average annual return since 2021 is shown above.
The Average Annual Return on the NLSP average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NLSP average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NLSP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|